However, previous studies have reported that elevated PRSS2 expression correlates with poor prognosis in gastric [9], breast, and prostate cancers [11], and promotes epithelial–mesenchymal transition in gastric cancer by upregulating MMP-9 [17]. Here, PRSS2 is linked to prostate carcinoma.